Transplant Rejection Types for USMLE: Recognize the Clock

Learn hyperacute, acute, chronic transplant rejection and GVHD for USMLE Step 1 & Step 2 CK. Use timing, pathology, and mechanisms to recognize each pattern.

Transplant Rejection — Recognize the Clock for USMLE Step 1 & Step 2 CK

Transplant rejection is a classic **“timing + pathology”** topic that shows up repeatedly on **USMLE Step 1** and **USMLE Step 2 CK**. Questions often give you:

• When the graft failed (minutes, weeks, or years)
• A brief description of the graft’s appearance or biopsy
• A clue about immune mechanisms or drug levels

Your job is to **recognize the clock** and match it to the correct type of rejection:

• **Hyperacute** — minutes to hours, preformed antibodies, type II hypersensitivity
• **Acute** — weeks to months, T-cell and/or antibody-mediated
• **Chronic** — months to years, progressive fibrosis and vascular narrowing
• **GVHD** — donor T cells attacking recipient (especially after bone marrow transplant)

Understanding these patterns helps you answer mechanism, pathology, and management questions quickly and confidently.

---

Pathophysiology: Immune Attack on the Graft

Transplant rejection occurs when **recipient immune responses** are directed against **donor antigens**, most importantly **donor MHC (HLA) molecules** and blood group antigens.

The **time course** and **histopathologic findings** are your key clues to the underlying mechanism:

Overview Table: Types of Transplant Rejection

| Type | Timing | Core Mechanism | |--------------------------|------------------------------|----------------------------------------------------------------| | **Hyperacute rejection** | Minutes–hours after reperfusion | **Preformed antibodies** (anti-ABO or anti-HLA) → type II hypersensitivity | | **Acute rejection** | Weeks–months | **T-cell and/or humoral response** to donor MHC | | **Chronic rejection** | Months–years | **Progressive, low-grade immune injury** with fibrosis | | **GVHD** | Variable | **Donor T cells** attack recipient tissues |

Each type has a distinct immunologic mechanism and characteristic pathology that guide prevention and treatment.

---

Hyperacute Rejection

Mechanism

Hyperacute rejection is driven by **preformed recipient antibodies** against donor antigens:

• Antibodies are typically **anti-ABO** or **anti-HLA**.
• They bind **donor endothelial antigens** immediately after reperfusion.
• This triggers a **type II hypersensitivity reaction** with **complement activation**.
• Result: **complement-mediated endothelial damage** and **widespread thrombosis** of graft vessels.

This process is **rapid and catastrophic**, leading to **immediate graft failure**.

Pathology and Gross Appearance

Pathologic changes include:

• **Widespread thrombosis** of graft vessels
• **Ischemic necrosis** of the graft

Grossly, the graft:

• Appears **mottled, cyanotic, and flaccid**
• Becomes **nonfunctional within minutes** after anastomosis

Prevention and Treatment

• **Prevention:**
• **Crossmatch testing** for **ABO and HLA compatibility** is essential.
• **Treatment:**
• Hyperacute rejection is **irreversible**.
• **Graft removal is required**; there is **no salvage therapy**.

Step 1 Focus

• Recognize hyperacute rejection as a **type II hypersensitivity reaction** due to **preformed antibodies**.
• Expect **complement-mediated endothelial damage** and **thrombosis**.
• High-yield prevention: **crossmatch testing** for ABO/HLA.

Step 2 CK Focus

• Clinical clue: graft becomes **cyanotic and nonfunctional immediately** after anastomosis.
• Management: **prompt graft removal**; **no effective rescue therapy**.
• Emphasis on **prevention through proper donor–recipient matching**.

---

Acute Rejection

Timing

• Occurs **weeks to months** after transplantation.
• May appear **earlier** if **immunosuppression is subtherapeutic**.

Mechanisms

Acute rejection can be **cellular (T-cell mediated)**, **humoral (antibody-mediated)**, or both.

Cellular (T-cell–mediated) Acute Rejection

• **Recipient cytotoxic T cells** recognize **donor MHC antigens**.
• They attack graft tissue, leading to:
• **Interstitial lymphocytic infiltrates**
• **Endotheliitis** (inflammation of the vascular endothelium)
• This is a **type IV hypersensitivity reaction**.

Humoral (Antibody-mediated) Acute Rejection

• **De novo anti-donor antibodies** form after transplantation.
• These antibodies cause:
• **Vasculitis**
• **Complement deposition**, often **C4d positive**

Both forms **target donor MHC antigens**, but the histology differs.

Treatment

Management focuses on **intensifying immunosuppression**:

• **Corticosteroids**
• **Calcineurin inhibitors** (e.g., **tacrolimus**, **cyclosporine**)
• **Lymphocyte-depleting agents** (e.g., **anti-thymocyte globulin**)

Ensuring **therapeutic drug levels** is critical to prevent and treat acute rejection.

Step 1 Focus

• Differentiate:
• **T-cell–mediated rejection** → **cellular infiltrates**, **type IV hypersensitivity**
• **Antibody-mediated rejection** → **vasculitis**, **complement deposition (C4d+)**
• Both forms are directed against **donor MHC antigens**.

Step 2 CK Focus

• Look for **rising creatinine** or **declining graft function** **weeks after transplant**.
• **Biopsy** is key and shows **lymphocytic infiltrate** (for cellular rejection).
• Management: **escalate immunosuppression** and ensure **adequate drug levels**.

---

Chronic Rejection

Timing

• Develops **months to years** after transplantation.

Mechanism

Chronic rejection reflects a **chronic, low-grade immune response** that involves **both cellular and humoral components**:

• Leads to **fibrosis**
• Causes **progressive vascular narrowing** (also called **obliterative vasculopathy**)

This is a **long-term, smoldering immune injury** rather than an acute attack.

Pathology

Key histologic features include:

• **Interstitial fibrosis**
• **Vascular smooth muscle proliferation**
• **Parenchymal atrophy**

Different transplanted organs show **characteristic chronic changes**:

| Organ | Characteristic Pathology in Chronic Rejection | |--------|---------------------------------------------------------| | Lung | **Bronchiolitis obliterans** | | Kidney | **Transplant glomerulopathy** | | Liver | **Vanishing bile duct syndrome** | | Heart | **Accelerated coronary arteriosclerosis** |

Treatment and Prognosis

• Chronic rejection is **often refractory** to therapy.
• **Prevention** and **optimal immunosuppression** are the main strategies.
• The process is generally **irreversible** and may ultimately require **re-transplantation**.

Step 1 Focus

• Recognize chronic rejection as a **mixed immune mechanism** (cellular + humoral).
• Hallmarks: **vascular fibrosis** and **parenchymal atrophy**.
• Understand that it is **irreversible** and reflects **long-term immune injury**.

Step 2 CK Focus

• Think of **progressive graft dysfunction** **months to years** after transplant **despite adequate immunosuppression**.
• Biopsy shows **interstitial fibrosis** and **vascular changes**.
• Focus on **long-term management** and **re-transplantation options**.

---

Graft-versus-Host Disease (GVHD)

GVHD is conceptually distinct from classic rejection because the **direction of immune attack is reversed**.

Setting and Mechanism

• Occurs when **immunocompetent donor T cells** attack **recipient tissues** that they recognize as foreign.
• Common settings:
• **Bone marrow transplantation**
• **Transfusion** in **severely immunodeficient patients**

This is a **type IV hypersensitivity reaction** mediated by **donor T cells**.

Clinical Features

GVHD typically presents with:

• **Diffuse maculopapular rash**
• **Diarrhea**
• **Jaundice**
• **Elevated liver enzymes**
• **Pancytopenia** due to **marrow suppression**

Prevention and Management

• **Prevention:**
• **Irradiation of donor blood products** for **immunocompromised recipients** to inactivate donor lymphocytes.
• **Treatment:**
• **Supportive therapy**
• **Immunosuppression** (e.g., **corticosteroids**)

Step 1 Focus

• Remember GVHD as a **type IV hypersensitivity** where **donor T cells recognize host antigens**.
• Distinguish it from **host-versus-graft rejection**, where the **recipient** attacks the **graft**.

Step 2 CK Focus

• Classic scenario: **post–bone marrow transplant** patient with **rash, diarrhea, and elevated liver enzymes**.
• Management centers on **supportive care**, **immunosuppression**, and **prevention with irradiated blood products**.

---

Diagnostic Approach: Using Time, Biopsy, and Clinical Clues

On exams, you rarely get full workups. Instead, you get **time since transplant**, **clinical status**, and sometimes **biopsy findings**.

Key patterns:

• **Minutes–hours after reperfusion** + **cyanotic, flaccid graft** → **hyperacute rejection**
• **Weeks–months** + **rising creatinine/declining function** + **lymphocytic infiltrate** → **acute T-cell–mediated rejection**
• **Months–years** + **progressive dysfunction** despite adequate immunosuppression + **fibrosis and vascular changes** → **chronic rejection**
• **Post–bone marrow transplant** + **rash, diarrhea, liver injury, pancytopenia** → **GVHD**

Biopsy and histology are especially important for distinguishing **acute cellular vs antibody-mediated** rejection and for confirming **chronic changes**.

---

Management & Prevention Strategies

Hyperacute Rejection

• **Prevention:**
• Careful **ABO and HLA crossmatching** before transplant.
• **Treatment:**
• **Irreversible** → **graft removal**.

Acute Rejection

• **Treatment:**
• **Intensify immunosuppression**:
• **Corticosteroids**
• **Calcineurin inhibitors** (tacrolimus, cyclosporine)
• **Lymphocyte-depleting agents** (anti-thymocyte globulin)
• Ensure **therapeutic drug levels**.

Chronic Rejection

• **Prevention:**
• Maintain **optimal immunosuppression** to minimize long-term immune injury.
• **Treatment:**
• Often **refractory**; focus on **long-term management** and **planning for re-transplantation**.

GVHD

• **Prevention:**
• **Irradiate donor blood products** for **immunocompromised recipients**.
• **Treatment:**
• **Supportive therapy**
• **Immunosuppression** (e.g., corticosteroids)

---

High-Yield Differentials & Common Pitfalls

Quick Comparison Table

| Condition | Who attacks whom? | Timing | Key Features | |------------------------|------------------------------------|---------------------|---------------------------------------------------| | Hyperacute rejection | **Recipient antibodies → graft** | Minutes–hours | Thrombosis, ischemic necrosis, cyanotic graft | | Acute rejection | **Recipient T cells/antibodies → graft** | Weeks–months | Lymphocytic infiltrate, vasculitis, C4d+ (humoral) | | Chronic rejection | **Recipient immune system → graft** | Months–years | Fibrosis, vascular narrowing, parenchymal atrophy | | GVHD | **Donor T cells → recipient** | Variable | Rash, diarrhea, jaundice, pancytopenia |

Common Exam Pitfalls

• **Confusing hyperacute vs acute rejection**:
• Hyperacute: **immediate**, **preformed antibodies**, **no salvage**.
• Acute: **weeks–months**, **de novo immune response**, **treatable** with immunosuppression.

• **Missing the type of hypersensitivity**:
• Hyperacute: **type II** (antibody-mediated, complement, thrombosis).
• Acute cellular and GVHD: **type IV** (T-cell mediated).

• **Forgetting GVHD directionality**:
• GVHD: **donor T cells attack recipient**.
• Classic rejection: **recipient immune system attacks graft**.

• **Overlooking chronic rejection irreversibility**:
• Chronic rejection is **irreversible** and **often refractory** to therapy.

---

Exam Vignette with Stepwise Reasoning

**Vignette:**

A 45-year-old man undergoes a kidney transplant. The surgery is uneventful, but within 30 minutes of reperfusion, the transplanted kidney becomes swollen, mottled, and cyanotic. Urine output is minimal, and the graft is flaccid and nonfunctional. The transplant team decides to remove the graft. Which of the following best explains this complication?

**Stepwise reasoning:**

• **Timing:** Minutes after reperfusion → suggests **hyperacute rejection**.
• **Clinical description:** Graft is **mottled, cyanotic, flaccid**, and **immediately nonfunctional** → matches **widespread thrombosis and ischemic necrosis**.
• **Mechanism:** Hyperacute rejection is due to **preformed recipient antibodies** (anti-ABO or anti-HLA) binding **donor endothelial antigens**.
• **Immunologic type:** This is a **type II hypersensitivity reaction** with **complement activation**.
• **Outcome:** Damage is **irreversible**, requiring **graft removal**.

Correct conceptual answer: **Preformed anti-donor antibodies causing a type II hypersensitivity reaction with complement-mediated endothelial injury and thrombosis.**

---

Key Takeaways

• **Use the clock:**
• **Minutes–hours** → **hyperacute**, preformed antibodies, type II, irreversible.
• **Weeks–months** → **acute**, T-cell and/or antibody-mediated, treatable with immunosuppression.
• **Months–years** → **chronic**, mixed immune mechanism, fibrosis and vascular narrowing, often irreversible.

• **Match pathology to mechanism:**
• Hyperacute: **thrombosis**, **ischemic necrosis**.
• Acute cellular: **interstitial lymphocytic infiltrates**, **endotheliitis**.
• Acute humoral: **vasculitis**, **C4d+ complement deposition**.
• Chronic: **interstitial fibrosis**, **vascular smooth muscle proliferation**, **parenchymal atrophy**.

• **GVHD is reversed:** **Donor T cells** attack **recipient tissues**, causing rash, diarrhea, jaundice, and pancytopenia; prevent with **irradiated blood products**.

• **Prevention is crucial:**
• Hyperacute: **ABO/HLA crossmatch**.
• GVHD: **Irradiate donor blood products**.
• Chronic: Maintain **optimal long-term immunosuppression**.

---

Keep Learning

Transplant rejection integrates **immunology, pathology, and clinical medicine**, making it a favorite for both **USMLE Step 1** and **USMLE Step 2 CK**. To deepen your understanding, connect these patterns with other hypersensitivity reactions and immunosuppressive drug mechanisms as you build your broader immunology framework. For more structured review strategies and core topics, explore additional resources on our main learning hub at /core-concepts and keep reinforcing these timelines and histologic patterns with practice questions.